lapatinib has been researched along with epidermal growth factor in 26 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (epidermal growth factor) | Trials (epidermal growth factor) | Recent Studies (post-2010) (epidermal growth factor) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 24,155 | 217 | 4,699 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (26.92) | 29.6817 |
| 2010's | 17 (65.38) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Alligood, KJ; Keith, BR; Liu, LH; Ma, H; Mullin, RJ; Owens, G; Rusnak, DW; Spector, NL; Xia, W | 1 |
| Burtness, B | 1 |
| Boyce, SH; Gay, RE; Gay, S; Huber, LC; Ink, BS; Künzler, P; Michel, BA | 1 |
| Agulnik, M; Brown, S; Chen, EX; Cohen, EW; Cohen, RB; Dancey, JE; Daneshmand, M; Hayes, DN; Ho, J; Hotte, SJ; Laurie, S; Lorimer, I; Pond, GR; Siu, LL; Tsao, MS; Vokes, EE; Winquist, E | 1 |
| Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L | 1 |
| Brown, PH; Gilmer, TM; Hill, JL; Hilsenbeck, SG; Kim, HT; Li, Y; Osborne, CK; Sexton, KR; Shen, Q; Strecker, TE; Wang, C; Zhang, Y | 1 |
| Griffiths, TR; Kriajevska, M; Manson, MM; McHugh, LA; Mejlvang, J; Mellon, JK; Sayan, AE; Sun, Y; Tulchinsky, E | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
| Breen, L; Clynes, M; Collins, DM; Dunne, G; O'Connor, R; Roche, S | 1 |
| Fujita, KA; Kubota, H; Kuroda, S; Ozaki, Y; Toyoshima, Y; Uda, S | 1 |
| Dao-Pick, T; DeFazio-Eli, L; Goodman, L; Parry, G; Strommen, K; Winslow, J | 1 |
| Chefrour, M; Ciccolini, J; Denden, A; Fischel, JL; Formento, P; Giacometti, S; Iliadis, A; Milano, G; Renée, N | 1 |
| Ahmad, ZK; Brown, CM; Cueva, RA; Doherty, JK; Ryan, AF | 1 |
| Breindl, S; Brockhoff, G; Buchholz, S; Diermeier-Daucher, S; Ortmann, O | 1 |
| Cole, PA; Head, S; Kim, K; Leahy, DJ; Longo, PA; Tarrant, MK; Wang, Z | 1 |
| Bernhard, JC; Gross-Goupil, M; Ravaud, A | 1 |
| Deng, X; Erfani, SF; Hemler, ME; Hoff, J; Jin, H; Kaetzel, DM; Li, Q; Novak, M; Rabinovitz, I; Sharma, C; Sonnenberg, A; Stipp, CS; Yang, H; Yang, XH; Yi, Y; Zhou, P | 1 |
| Contini, A; Erne, P; Ferri, N; Frachet, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ | 1 |
| Andrianifahanana, M; Becker, J; Edens, M; Gupta, SK; Leof, EB; Maidl, E; Rahimi, RA; Repellin, CE; Wilkes, MC; Wittenberger, J; Yin, X | 1 |
| Fujii, H; Izawa, S; Kiessling, R; Kono, K; Kua, LF; Mimura, K; Mueller, A; Seliger, B; Shiraishi, K; So, J; Yong, WP | 1 |
| Conklin, DS; Khan, F; Kokabee, L; Sevinsky, CJ; Sun, Y; Wang, X; Wong, J | 1 |
| Kannan, N; Katiyar, S; Ruan, Z | 1 |
| Chacko, AR; Hilkens, J; Piyush, T; Rhodes, JM; Sindrewicz, P; Yu, LG | 1 |
| Band, H; Band, V; Mirza, S; Mohibi, S; Srivastava, S | 1 |
| Alifia, J; Bindhya, S; Ganesan, TS; Garg, M; Krishnapriya, S; Kumar, V; Manasa, P; Patole, C; Shabna, A; Sidhanth, C | 1 |
| Acconcia, F | 1 |
2 review(s) available for lapatinib and epidermal growth factor
| Article | Year |
|---|---|
Her signaling in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
Lapatinib and renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Humans; Kidney Neoplasms; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
1 trial(s) available for lapatinib and epidermal growth factor
| Article | Year |
|---|---|
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Disease-Free Survival; Epidermal Growth Factor; Female; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Salivary Gland Neoplasms; Treatment Outcome | 2007 |
23 other study(ies) available for lapatinib and epidermal growth factor
| Article | Year |
|---|---|
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured | 2002 |
Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts.
Topics: Apoptosis; Arthritis, Rheumatoid; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Epidermal Growth Factor; Fibroblasts; Gene Expression Regulation; Humans; Inflammation Mediators; Lapatinib; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Synovial Membrane | 2008 |
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclin D1; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Precancerous Conditions; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2009 |
Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Separation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Humans; Inhibitory Concentration 50; Lapatinib; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |
Modulation of P-gp expression by lapatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Decoupling of receptor and downstream signals in the Akt pathway by its low-pass filter characteristics.
Topics: Animals; Epidermal Growth Factor; ErbB Receptors; Immunoblotting; Lapatinib; Models, Biological; PC12 Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Ribosomal Protein S6; Signal Transduction | 2010 |
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Signal Transduction; Staining and Labeling; Treatment Outcome | 2011 |
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2012 |
ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.
Topics: Benzothiazoles; Cell Cycle; Cell Proliferation; Epidermal Growth Factor; Humans; Lapatinib; Neuroma, Acoustic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2011 |
Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; Female; Humans; Lapatinib; Neuregulin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
Mechanistic insights into the activation of oncogenic forms of EGF receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Epidermal Growth Factor; ErbB Receptors; HEK293 Cells; Humans; Kinetics; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Quinazolines; Tumor Suppressor Proteins | 2011 |
Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis.
Topics: Animals; Butadienes; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; Female; Focal Adhesion Kinase 1; Humans; Integrin alpha6beta4; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tetraspanin 24; Transendothelial and Transepithelial Migration | 2012 |
Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
Topics: Cadherins; Cell Communication; Cell Line, Tumor; Cytoskeleton; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction | 2013 |
Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.
Topics: Animals; Benzamides; Bleomycin; Cell Line; Drug Interactions; Epidermal Growth Factor; ErbB Receptors; Feedback, Physiological; Imatinib Mesylate; Lapatinib; Lung; Mice; Myofibroblasts; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pulmonary Gas Exchange; Pyrimidines; Quinazolines; Receptor, ErbB-2; Receptors, Platelet-Derived Growth Factor; Transforming Growth Factor beta; Up-Regulation | 2013 |
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
Topics: Androstadienes; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; HLA-A Antigens; Humans; Lapatinib; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Wortmannin | 2013 |
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Epidermal Growth Factor; Female; Gene Expression; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Neuregulin-1; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Topics: Allosteric Regulation; Amino Acid Motifs; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Drug Resistance; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Immunoblotting; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines | 2017 |
Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells.
Topics: Blood Proteins; Cell Line, Tumor; Cell Membrane; Endocytosis; Enzyme Activation; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Galectin 3; Galectins; Humans; Lapatinib; MAP Kinase Signaling System; Mucin-1; Mutation; Neoplasms; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines | 2017 |
Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.
Topics: Acetylation; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gene Knockdown Techniques; Humans; Lapatinib; Models, Biological; Mutation; p300-CBP Transcription Factors; Phosphorylation; Protein Stability; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factors; Ubiquitination | 2017 |
Phosphoproteome of signaling by ErbB2 in ovarian cancer cells.
Topics: Aldehyde Reductase; Cell Line, Tumor; Epidermal Growth Factor; Female; Humans; Lapatinib; Ovarian Neoplasms; Phosphoproteins; Receptor, ErbB-2 | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |